ERBB2 and breast cancer: In BC, the majority of TAAs studied as BC vaccines are the HER2 protein and other HER2-derived peptides (204), MUC-1 (206), and a number of cancer testis antigens including KK-LC-1, NY-ESO-1, and MAGEA1 (204), with NY-ESO-1, and MAGEA1 as major TAAs also in LC (99, 105, 106).